Nonalcoholic fatty liver disease progression rates to cirrhosis and progression of cirrhosis to decompensation and mortality: a real world analysis of Medicare data

Risk factors and timing associated with disease progression and mortality in nonalcoholic fatty liver disease (NAFLD) are poorly understood.

[1]  Suying Li,et al.  Disease Severity Is Associated With Higher Healthcare Utilization in Nonalcoholic Steatohepatitis Medicare Patients. , 2019, The American journal of gastroenterology.

[2]  Z. Goodman,et al.  The Natural History of Advanced Fibrosis Due to Nonalcoholic Steatohepatitis: Data From the Simtuzumab Trials , 2019, Hepatology.

[3]  N. Chalasani,et al.  Characteristics, aetiologies and trends of hepatocellular carcinoma in patients without cirrhosis: a United States multicentre study , 2019, Alimentary pharmacology & therapeutics.

[4]  J. Hodson,et al.  Outcomes of liver transplantation for non-alcoholic steatohepatitis: A European Liver Transplant Registry study , 2019, Journal of hepatology.

[5]  M. Rinella,et al.  Nonalcoholic Fatty Liver Disease: Identification and Management of High-Risk Patients. , 2019, The American journal of gastroenterology.

[6]  G. Dusheiko,et al.  Advancing Age and Comorbidity in a US Insured Population‐Based Cohort of Patients With Chronic Hepatitis B , 2019, Hepatology.

[7]  Hongliang Li,et al.  Insights into the Epidemiology, Pathogenesis, and Therapeutics of Nonalcoholic Fatty Liver Diseases , 2018, Advanced science.

[8]  M. Manns,et al.  Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016-2030. , 2018, Journal of hepatology.

[9]  Michael Charlton,et al.  The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases , 2018, Hepatology.

[10]  M. A. Khan,et al.  Clinical epidemiology and disease burden of nonalcoholic fatty liver disease , 2017, World journal of gastroenterology.

[11]  P. Puri,et al.  Liver Transplantation for Nonalcoholic Steatohepatitis in the US: Temporal Trends and Outcomes , 2017, Digestive Diseases and Sciences.

[12]  A. Collins,et al.  Use of the Medicare database in epidemiologic and health services research: a valuable source of real-world evidence on the older and disabled populations in the US , 2017, Clinical epidemiology.

[13]  V. Wong,et al.  Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: Systematic review and meta‐analysis , 2017, Hepatology.

[14]  Z. Goodman,et al.  Changes in Fibrosis, but not the Nafld Activity Score (NAS), are Associated with Disease Progression in Patients with Nonalcoholic Steatohepatitis (NASH) and Advanced Fibrosis , 2017 .

[15]  D. Thorburn,et al.  Pharmacological interventions for non-alcohol related fatty liver disease (NAFLD): an attempted network meta-analysis. , 2017, The Cochrane database of systematic reviews.

[16]  A. Lonardo,et al.  Fatty liver is associated with an increased risk of diabetes and cardiovascular disease - Evidence from three different disease models: NAFLD, HCV and HIV , 2016, World journal of gastroenterology.

[17]  Y. Rotman,et al.  Current and upcoming pharmacotherapy for non-alcoholic fatty liver disease , 2016, Gut.

[18]  Lynne Pearce,et al.  Non-alcoholic fatty liver disease. , 2016, Nursing standard (Royal College of Nursing (Great Britain) : 1987).

[19]  E. Bjornsson,et al.  Liver Fibrosis, but No Other Histologic Features, Is Associated With Long-term Outcomes of Patients With Nonalcoholic Fatty Liver Disease. , 2015, Gastroenterology.

[20]  Monjur Ahmed,et al.  Non-alcoholic fatty liver disease in 2015. , 2015, World journal of hepatology.

[21]  Mary E Rinella,et al.  Nonalcoholic fatty liver disease: a systematic review. , 2015, JAMA.

[22]  Mats Fredrikson,et al.  Fibrosis stage is the strongest predictor for disease‐specific mortality in NAFLD after up to 33 years of follow‐up , 2015, Hepatology.

[23]  Zhen Wang,et al.  Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis: a systematic review and meta-analysis of paired-biopsy studies. , 2015, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[24]  Q. Anstee,et al.  Non-alcoholic fatty liver disease: a practical approach to treatment , 2014, Frontline Gastroenterology.

[25]  Raj Vuppalanchi,et al.  Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: Selected practical issues in their evaluation and management , 2009, Hepatology.

[26]  Z. Younossi,et al.  Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. , 1999, Gastroenterology.

[27]  L. Henry,et al.  NAFLD AND NASH: Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention , 2018 .

[28]  Robert S. Brown,et al.  Noninvasive Measures of Liver Fibrosis and Severity of Liver Disease. , 2016, Gastroenterology & hepatology.